Korro Bio Inc. has announced a submission to the Australian Bellberry Human Research Ethics Committee (HREC) for a phase I/II study of KRRO-110 for α-1 antitrypsin deficiency (AATD).

Fractyl Health Inc. has nominated RJVA-002, a GIP/GLP-1 dual agonist, as its first pancreatic gene therapy candidate for obesity.

Endevica Bio Inc. has announced the spin-off of a newly created company, Abisati LLC, to develop an oral melanocortin MC4 receptor agonist, 710GO, as a weight loss therapy.

Previous studies have shown that NETosis, a specialized form of neutrophil-specific cell death, is involved in the pathogenesis of diabetes.

Be Biopharma Inc. has developed a CRISPR/Cas9-based precision B-cell gene therapy to deliver active tissue non-specific alkaline phosphatase (ALP) for the potential treatment of hypophosphatasia (HPP).

Cardiovascular disease is among the leading causes of death in individuals with type 2 diabetes. The role that microRNA 210 (miR-210) plays in endothelial cells and in diabetes-driven endothelial dysfunction is not clearly understood. Its potential as a therapeutic target was investigated.

According to World Health Organization data, endometriosis affects about 10% of reproductive-age females globally. That already makes endometriosis a wildly underresearched and underfunded disease in relation to its prevalence. Plus, Rama Kommagani thinks even 10% is an underestimation. “Diagnosis is very underreported, particularly in low- and middle-income countries,” Kommagani, who is an associate professor of pathology at Baylor College of Medicine, told BioWorld.